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anxieshi@yahoo.cAbstract 3-Hydroxymethyl-4-methyl-DCK (3, HMDCK) was discovered previously as a potent
HIV non-nucleoside reverse transcriptase inhibitor (NNRTIs) (EC50: 0.004 mM, TI: 6225) with a
novel mechanism of action. It exerts anti-HIV activity by inhibiting the production of HIV-1
double-stranded viral DNA from a single-stranded DNA intermediate, rather than blocking the
generation of single-stranded DNA from a RNA template, which is the mechanism of action of
current HIV-1 RT inhibitors. However, the insufﬁcient metabolic stability of 3 limits its further
clinical development. In the current study, a series of ester prodrugs of 3 was designed and
synthesized to explore the new drug candidates as NNRTIs. The L-alanine ester prodrug 10
exhibited desirable pharmacokinetic properties in vitro and in vivo and showed improved oral
bioavailability of 26% in rat, and would be a potential clinical candidate as a new anti-AIDS drug.
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Huanfang Guo et al.2141. Introduction
With approximately 4.2 million HIV/AIDS patients world-
wide, 26 current anti-HIV drugs including reverse transcrip-
tase (RT), protease, integrase, and entry inhibitors are used
alone or in combination to treat HIV infection and AIDS
patients. However, HIV develops resistance to all current
drugs, resulting in rapidly decreased drug efﬁcacy. Therefore,
new anti-HIV agents with novel structures or mechanism(s) of
action are urgently needed to overcome this problem.
In our previous studies, 30,40-di-O-(S)-camphanoyl-(þ)-cis-
khellactone (1, DCK, Fig. 1) and its analogs were identiﬁed as a
novel class of potent anti-HIV agents1–4 acting by a unique
mechanism. These compounds inhibit the production of HIV-1
double-stranded viral DNA from a single-stranded DNA
intermediate5, in contrast to current HIV-1 RT inhibitors that
block the generation of single-stranded DNA from a RNA
template. Due to the novel mechanism of action, we were
strongly motivated to develop potent DCK analogs as potential
clinical candidates. Due to the high potency (EC50: 0.0015 mM,
TI: 15,733) and easy synthesis, 4-methyl-DCK (2) was ﬁrst
selected as a candidate for preclinical studies. However, its high
hydrophobicity resulted in poor bioavailability. Subsequent
structure modiﬁcation then focused on the 3-position of the
coumarin ring of 2 via the addition of polar functionalities toO
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Scheme 1 Synthesis of prodrugs. (i) oxalyl chloride or succinic anhyd
amino acid(s), Et3N/acetone; (iv) TFA/CH2Cl2; (v) HCl in diethyl ethimprove water-solubility and enhance drug oral absorption and
bioavailability. Consequently, 3-hydroxymethyl-4-methyl-DCK
(3, HMDCK) was discovered to be a potential drug candidate
with high potency (EC50: 0.004 mM, TI: 6225) and moderate
bioavailabity (F: 15%) in rat. However, further studies revealed
that 3 lacked sufﬁcient metabolic stability, preventing further
development of this compound class.6
Therefore, our current research has turned to improve
DCK analogs’ pharmacokinetic properties and eventually
enhance oral availability. Because the hydroxy group at the
3-positon of the coumarin ring of 3 is a good ‘‘handle’’,
compound 3 served as the new starting point for the design of
prodrugs, which has proven to be a successful approach in
development of new marketed drugs, including chloramphe-
nicol succinate, docarpamine7, valganciclovir8, valaciclovir,
and others. Our prodrug design focused on masking the
hydroxy group at the 3-positon of the coumarin ring of 3 by
introducing polar functional groups selected to decrease the
rapid metabolism of parent compound by such conjugation as
well as improve molecular water-solubility and absorption9.
Therefore, nine ester prodrugs (5–13) with a free carboxylic or
amine group were designed and synthesized, and their phar-
macokinetic properties and metablic stabilities were evaluated
in vitro and in vivo.2. Results and discussion
2.1. Chemistry
As shown in Scheme 1, the hydroxy group of 3 reacted with
oxalyl chloride or succinic anhydride (molar ratio 1:1.1) in the
presence of pyridine to provide carboxylic ester prodrugs 5
and 6, respectively. Next, 5 and 6 were converted to corre-
sponding sodium carboxylates 7 and 8, respectively, by using
sodium 2-ethylhexanoate. We also synthesized amino acid
ester prodrugs 9–12 by using 3-bromomethyl-4-methyl-DCK
(4) treated with N-Boc protected natural glycine, analine,
valine, or leucine, respectively, in the presence of triethylamineOC(CH2)nCOOR1
O
n = 0,   5 R1 = H, 7 R1 = Na 
n = 2,   6 R1 = H, 8 R1 = Na
ii
vi O OO
OR
OR
OCCHR1
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HR1
Boc
  9  R1 = H
10  R1 = CH3
11  R1 = CH2(CH3)2
12  R1 = CH2CH(CH3)2
v 13  R'NH2  HCl
ride, Py/CH2Cl2; (ii) sodium 2-ethylhexanoate/EtOAc; (iii) N-Boc-
er.
Prodrug design, synthesis and evaluation of (30R, 40R)-3, HMDCK 215in acetone, followed by hydrolysis in triﬂuoroacetic acid, with
yields of over 50%. Furthermore, the free base of 9 was
treated with hydrogen chloride in ether to form the corre-
sponding HCl salt 13.2.2. In vitro evaluation
The in vitro metabolic stabilities of the ester prodrugs 5–13
were ﬁrst investigated using Sprague-Dawley rat liver micro-
somes under oxidative conditions, together with the parent
compound 3 and a reference compounds propranolol (PRO).
The incubation mixtures of 5–13 were analyzed by analytical
HPLC with MS detector to measure the release and consump-
tion of the parent compound 3 at different time points (5, 15,
30, and 60 min). A linear relationship (R240.95) was found
between the logarithm of the percentage of 3 remaining using
0 min peak height ratio as 100% versus time for all tested
compounds, which was evidence of pseudo-ﬁrst-order degra-
dation kinetics. The results of the in vitro metabolic evaluation
are summarized in Table 1 and Fig. 2, including the degrada-
tion rate constants (kobs), the corresponding apparent half-life
(T1/2), and intrinsic clearance (CLint) of prodrugs 5–13.
From the results, we can see that all prodrugs could release
quickly and showed over 50 percent quantity of parent
compound 3 at least at the 5 min time point. Except for 9,
most of the ester prodrugs showed a longer half life (T1/2
25.93–49.26 min) compared with parent compound 3 (T1/2
17.92 min). The L-analine ester prodrug 10 was the best
compound with the longest apparent half-time in vitro T1/2
of 49.26 min, the lowest degradation rate constant (kobs 0.014),
and CLint of 0.14 mL/min/mg among this prodrug series. In
contrast with 10, the glycine ester prodrug 9 was much less
stable (T1/2 3.90 min) than 3, thus indicating that a methyl side
chain in the amino acid must be necessary to slow down the
release of the parent compound 3 from the prodrug. With T1/2
values ranging from 25.93 to 35.27 min, prodrugs 5–8 with a
free carboxylic group or related sodium salt also showed
longer metabolic half-lives compared with 3. Thus, our current
ester prodrugs, prepared by introducing either carboxylic acids
or amino acids, successfully led to signiﬁcantly prolonged half-
lives, decreased degradation rates, and smaller intrinsic clear-
ance values compared with the parent compound 3. Subse-
quently, these new prodrugs were further evaluated in animal
models.Figure 2 In vitro metabolic stability in Sprague-Dawley rat liver
microsomes of prodrugs and parent compound (3) as well as
positive control drug propranolol (PRO).2.3. In vivo evaluation
In the in vivo evaluation, prodrugs 5–13 were administered
in 10% poly (ethylene glycol)-400 (PEG400) to adult maleTable 1 In vitro metabolic stability proﬁles of prodrugs together
Parameter Compound
3 5 6 7 8
kobs 0.039 0.020 0.020 0.024 0.0
T1/2 (min) 17.92 34.61 35.27 29.07 25.9
CLint (mL/min/mg) 0.39 0.20 0.20 0.24 0.2
aReference compounds: propranolol (moderate metabolism in vivo wSD rats (180–200 g) via an oral route (i.g. suspension, 20 mg/
kg), and 3 was administrated via oral and intravenous routes
with i.g. 20 mg/kg and i.v. 2 mg/kg, respectively, as a refer-
ence. Plasma samples for each tested compound were collected
at 6–8 time points over a 12-h period, immediately centrifuged,
and stored at 20 1C, successively. All samples were analyzed
with LC-MS/MS by measuring the concentration of parent
compound 3, which was released from each prodrug. The
pharmacokinetic parameters of prodrugs were calculated by
non-compartmental analysis using DAS Version 2.0. The data
are shown in Table 2 and Fig. 3.
The in vivo data indicated that L-analine ester prodrug 10
exhibited a better pharmacokinetic proﬁle than 3, with a higher
oral bioavailability (F: 25.7%), lower systemic clearance (CL:
0.016 L/min/kg), smaller volume of distribution (Vd: 0.045 L/kg),
and moderate MRT (1.793 h). Meanwhile, the high Cmax
(621.5 ng/mL) of 10 demonstrated that the presence of the
L-alanine moiety greatly beneﬁted drug absorption in vivo. With
a long Tmax (0.75 h), prodrug 10 slowly and smoothly released the
parent drug, allowing reduced metabolic opportunities for 3, and
subsequently enhancing oral bioavailability. On the other hand,
the prodrug 8, a sodium carboxylate salt of prodrug 6, exhibited
obviously improved oral bioavailability (F: 12.4%) comparing to
6 (F: 3.3%). The obvious differences of 8 and 6 in AUC (588.9
and 157.9 ngUh/mL, respectively) and Cmax (398.5 and 80.9 ng/
mL, respectively) values indicated that the increased dissolution
rate of a salt form improved absorption. Among these prodrugs,
the most promising prodrug was 10. It showed higher plasma
maximal concentration (Cmax: 10412ﬃ34remaining com-
pounds), lower clearance and volume of distribution (CL and
Vd: 10o12ﬃ3oremaining compounds) than the other prodrugs,
subsequently resulting in greatly increased drug absorption and
oral bioavailability (F%: 10434remaining compounds). Thesewith the parent drug in SD rat liver microsomes.
9 10 11 12 13 PROa
27 0.178 0.014 0.023 0.023 0.026 0.033
3 3.90 49.26 30.09 30.77 26.54 20.71
7 1.78 0.14 0.23 0.23 0.26 0.33
ith T1/2 of 3–5 h).
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Figure 3 Plasma concentration-versus-time curves of prodrugs
and parent compound. (A) 3 with PEG400, i.v. administration at
2 mg/kg, and (B) prodrugs and 3 with PEG400, i.g. administration
at 20 mg/kg. Results are averages of three independent assays.
Huanfang Guo et al.216in vivo results are consistent with the in vitro data. Thus, we
postulate that the presence of an amino acid moiety with a bulky
side chain might beneﬁt ‘‘drug-like’’ molecular physicochemical
properties, resulting in improved prodrug absorption and bioa-
vailability as shown in both in vitro and in vivo assays.2.4. Water solubility (WS) analysis
Because water solubility is a crucial physicochemical property
that affects drug absorption, the designed prodrugs contained a
polar structural moiety, either amino acid or carboxylic acid,
introduced to improve water solubility. We performed a WS
analysis to compare the most promising prodrug 10 and parent
compound 3. We ﬁrst prepared a solution of each compound in
acetonitrile at room temerature and diluted this stock solution
into ﬁve required different concentrations to establish a standard
curve. The water-solubility of each compound was determined by
HPLC analysis from the correlating area of its saturated
concentration in water. As shown in Table 3, prodrug 10 had
better aqueous solubility (18 mg/L) than 3 (8.4 mg/L). Further-
more, prodrug 10 also had a lower predicted octanol-water
partition coefﬁcient (log P) and distribution coefﬁcient (log D)
values (3.84 and 3.38) than those of 3 (4.44 and 4.43, respectively).
Based on its improved pharmacokinetic properties, prodrug 10
could merit further development as a drug candidate.
Table 3 Predicted log P and log D values and water
solubilities of 3 and 10.
Parameter Compound
3 10
Water solubility (mg/L, pH 7.4) 8.4 18
log P 4.44 3.84
log D (pH 7.4) 4.43 3.38
nThe octanol-water partition coefﬁcient log P and apparent
distribution coefﬁcient log D values were calculated by using
ACD programs.
Prodrug design, synthesis and evaluation of (30R, 40R)-3, HMDCK 2173. Conclusions
Ester prodrugs of 3, either carboxylic or amino acid esters,
were synthesized and evaluated in the current study, leading to
the discovery of the promising prodrug 10. It exhibited greatly
improved oral bioavailability and other desirable pharmaco-
kinetic properties, which were better than those of the parent
compound 3. These results suggested that prodrug 10 could be
further investigated as a potential new anti-AIDS NNRTI
drug candidate.4. Experimental
4.1. Chemistry
Melting points were measured with an RY-1 melting appara-
tus without correction. The proton nuclear magnetic reso-
nance (1H NMR) spectra were measured on a JNM-ECA-400
(400 MHz) spectrometer using tetramethylsilane (TMS) as the
internal standard. The solvent used was CDCl3, unless other-
wise indicated. Mass spectra (MS) were measured on an ABI
Perkin–Elmer Sciex API-150 mass spectrometer with electro-
spray ionization, and the relative intensity of each ion peak is
presented as percent (%). The purities of target compounds
were Z95%, measured by HPLC analyses, which were
performed on an Agilent 1100 HPLC system with a UV
detector. HPLC analyses for purity were performed using an
Agilent SC-C18 column (150 mm 4.6 mm, 5 mm) eluting
with a mixture of solvents A and B (Condition: acetonitrile/
water 70:30, ﬂow rate 1.0 mL/min), detected under UV
wavelength at 320 nm and an injection volume of 40 mL.
Thin-layer chromatography (TLC) and preparative TLC were
performed on silica gel GF254 plates. Silica gel (200–300 mesh)
from Qingdao Haiyang Chemical Company was used for
column chromatography. All chemicals were obtained from
Beijing Chemical Works or Sigma-Aldrich, Inc.
4.2. 2-Oxo-2-[(30,40-di-O-(S)-camphanoyl-4-methyl-(þ)-cis-
kellactone-3-yl)methoxy]acetic acid (5) and sodium salt (7)
Oxalyl chloride (0.1 mL) in anhydrous CH2Cl2 was added slowly
into a solution of 3 (133 mg, 0.2 mmol) in CH2Cl2 (20 mL,
anhydrous) at ice-bath temperature, and then at room tempera-
ture with stirring for 1 h. The progress was monitored by TLC
(acetone/cyclohexame 2:1) until the reaction was ﬁnished. The
mixture was poured into ice-water, and extracted with EtOActhree times. The combined organic phase was washed with water,
aq. NaHCO3, water, and brine successively, and dried over
anhydrous Na2SO4. After removal of solvent in vacuo, the residue
was puriﬁed by PTLC (eluent: acetone/cyclohexame 3:1) to obtain
108 mg of 5, yield 73%; light yellow solid, mp 208–210 1C; 1H
NMR d 0.98–1.12 (18H, m.s., 6CH3 in camphanoyl group),
1.45 and 1.49 (each 3H, s, CH3-2
0), 1.68, 1.93, 2.23, and 2.51 (each
2H, m, CH2 in camphanoyl group), 2.49 (3H, s, CH3-4), 5.17 (2H,
s, CH2-3), 5.33 (1H, d, J¼4.4 Hz, H-30), 6.56 (1H, d, J¼4.4 Hz,
H-40), 6.87 (1H, d, J¼9.2 Hz, H-6), 7.64 (1H, d, J¼9.2 Hz, H-5).
MS m/z (%) 739.3 (Mþ1, 4), 649.5 (M-89, 100); HPLC purity
96.14%. Compound 5 (77 mg, 0.1 mmol) in 2 mL of EtOAc with
18 mg of sodium 2-ethylhexanoate was stirred at room tempera-
ture for 12 h. The precipitated solid was collected and dried to
obtain the sodium salt 7, mp4230 1C; HPLC purity 95.36%.4.3. 4-Oxo-4-[(30,40-di-O-(S)-camphanoyl-4-methyl-(þ)-cis-
kellactone-3-yl)methoxy]butanoic acid (6) and sodium salt (8)
To a solution of 3 (133 mg, 0.2 mmol) in CH2Cl2 (20 mL,
anhydrous) was added 0.5 mL of pyridine and 20 mg of
succinic anhydride successively. The mixture was stirred at
room temperature for 12 h and monitored by TLC (acetone/
cyclohexane 1:1) to the reaction completion. The mixture was
added to 10 mL of aq. HCl (5%), and extracted with EtOAc
three times. The combined organic phase was washed with
water, aq. NaHCO3, water, and brine successively, and dried
over anhydrous Na2SO4. After removal of solvent in vacuo,
the residue was puriﬁed by PTLC (eluent: acetone/cyclohex-
ame 1:1) to obtain 86 mg of 6, yield 56%; light yellow solid,
mp 132–134 1C; 1H NMR d 0.98–1.12 (18H, m.s., 6CH3 in
camphanoyl group), 1.45 and 1.49 (each 3H, s, CH3-2
0), 1.68,
1.93, 2.23, and 2.51 (each 2H, m, CH2 in camphanoyl group),
2.48 (3H, s, CH3-4), 2.64 (4H, m, 2CH2 in side chain), 5.17
(2H, s, CH2-3), 5.40 (1H, d, J¼4.8 Hz, H-30), 6.63 (1H, d,
J¼4.8 Hz, H-40), 6.86 (1H, d, J¼9.2 Hz, H-6), 7.63 (1H, d,
J¼9.2 Hz, H-5). MS m/z (%) 767.4 (Mþ1, 27), 649.5 (M-117,
100); HPLC purity 97.12%. Compound 6 (77 mg, 0.1 mmol)
in 2 mL of EtOAc with 18 mg of sodium 2-ethylhexanoate was
stirred at room temperature for 12 h. The precipitated solid
was collected and dried to obtain the sodium salt 8, mp4230 1
C; HPLC purity 100.0%.4.4. General procedure for the preparation of
N-Boc-amino acids
To a solution of an amino acid (i.e., glycine, alanine, valine, or
leucine) (10 mmol) in 25 mL of water was added 0.5 g of
Na2CO3 with stirring until a complete solution was reached.
BOC anhydride (15 mmol) in 1,4-dioxane (10 mL) was added
to the above solution at 0 1C with stirring for 1 h, and then
stirring continued at room temperature for an additional 12 h.
The mixture was poured into water (25 mL) and washed with
EtOAc to remove unreacted anhydride. The water phase was
adjusted to pH 1 with aq. HCl (10%) and extracted with
EtOAc again three times. Next, the combined organic phase
was washed with water and brine successively, and dried with
anhydrous Na2SO4. After solvent was removed under reduced
pressure, the protected amino acid was used for the next
reaction without puriﬁcation.
Huanfang Guo et al.2184.5. General procedure for the preparation of ester
prodrugs 9–12
A mixture of 3-bromomethyl-4-methyl-DCK (4, 0.21 mmol) in
acetone (10 mL), Et3N (1 mL), and Boc-protected amino acid
(0.4 mmol) was stirred at room temperature for 1 h, and
monitored by TLC eluting with a mixture of petroleum ether
and EtOAc (3:1) until the reaction had ﬁnished. The mixture
was poured into ice-water and extracted with EtOAc three
times. The combined organic phase was washed with aq. HCl
(5%), water, aq. NaHCO3, water, and brine successively, and
dried over anhydrous Na2SO4. After removing solvent in
vacuo, solid crude product was puriﬁed by column chromato-
graph (gradient of EtOAc and petroleum ether 0–40%) to
provide corresponding ester products. The BOC group was
removed by treatment with CF3COOH (0.5 mL) in CH2Cl2
(2 mL) at room temperature with stirring for 1 h. The mixture
was poured into water, pH adjusted to 10 with Na2CO3, and
extraction performed with EtOAc three times. After removal
of solvent in vacuo, the crude product was puriﬁed by
preparative TLC (eluent: acetone/cyclohexane 2:1) to provide
corresponding pure ester prodrugs 9–12.4.5.1. [30,40-Di-O-(S)-camphanoyl-4-methyl-(þ)-cis-
kellactone-3-yl]methyl 2-aminoacetate (9)
Starting with 148 mg (0.21 mmol) of 4 and 70 mg of N-Boc
glycine to provide 76 mg of pure 9 as light yellow solid in 53%
yield, mp 192–194 1C; 1H NMR d 0.98–1.12 (18H, m.s.,
6CH3 in camphanoyl group), 1.45 and 1.50 (each 3H, s,
CH3-2
0), 1.69, 1.92, 2.20, and 2.51 (each 2H, m, CH2 in
camphanoyl group), 2.50 (3H, s, CH3-4), 3.45 (2H, s, CH2CO-
3), 5.20 (2H, s, CH2O-3), 5.40 (1H, d, J¼4.8 Hz, H-30), 6. 63
(1H, d, J¼4.8 Hz, H-40), 6.86 (1H, d, J¼8.8 Hz, H-6), 7.62
(1H, d, J¼8.8 Hz, H-5). MS m/z (%) 724.6 (Mþ1, 100);
HPLC purity 95.45%.4.5.2. [30,40-Di-O-(S)-camphanoyl-4-methyl-(þ)-cis-
kellactone-3-yl]methyl 2-aminopropanoate (10)
Starting with 148 mg (0.21 mmol) of 4 and 76 mg of N-Boc
alanine to provide 85 mg of pure 10 as light yellow solid in
58% yield, mp 178–180 1C; 1H NMR d 0.98–1.12 (18H, m.s.,
6CH3 in camphanoyl group), 1.32 (3H, d, J¼7.2 Hz,
alanine CH3), 1.45 and 1.49 (each 3H, s, CH3-2
0), 1.68, 1.93,
2.21, and 2.51 (each 2H, m, CH2 in camphanoyl group), 2.49
(3H, s, CH3-4), 3.56 (1H, m, CHCO-3), 5.18 (2H, s, CH2-3),
5.40 (1H, d, J¼4.8 Hz, H-30), 6.63 (1H, d, J¼4.8 Hz, H-40),
6.86 (1H, d, J¼8.8 Hz, H-6), 7.62 (1H, d, J¼8.8 Hz, H-5). MS
m/z (%) 738.1 (Mþ1, 100); HPLC purity 100.0%.4.5.3. [30,40-Di-O-(S)-camphanoyl-4-methyl-(þ)-cis-
kellactone-3-yl]methyl 2-amino-3-methyl-butanoate (11)
Starting with 148 mg (0.21 mmol) of 4 and 86 mg of N-Boc
valine to provide 83 mg of pure 11 as light yellow solid in 54%
yield, mp 150–152 1C; 1H NMR d 0.84–0.86 (6H, m, valine
2CH3), 0.98–1.12 (18H, m.s., 6CH3 in camphanoyl
group), 1.24 (1H, m, valine CH), 1.43 and 1.49 (each 3H, s,
CH3-2
0), 1.68, 1.93, 2.20, and 2.49 (each 2H, m, CH2 in
camphanoyl group), 2.49 (3H, s, CH3-4), 3.28 (1H, d, J¼4.8
Hz, NCHCO), 5.15 (2H, s, CH2-3), 5.38 (1H, d, J¼4.8 Hz, H-
30), 6.62 (1H, d, J¼4.8 Hz, H-40), 6.84 (1H, d, J¼8.8 Hz, H-6), 7.60 (1H, d, J¼8.8 Hz, H-5). MS m/z (%) 766.6 (Mþ1,
100), 649.5 (M-116, 86); HPLC purity 100.0%.
4.5.4. [30,40-Di-O-(S)-camphanoyl-4-methyl-(þ)-cis-
kellactone-3-yl]methyl 2-amino-4-methyl-pentanoate (12)
Starting with 148 mg of 4 and 92 mg of N-Boc leucine to
provide 102 mg of pure 12 as light yellow solid in 65% yield,
mp 158–160 1C; 1H NMR d 0.85 (6H, m, leucine 2CH3),
0.98–1.12 (18H, m.s., 6CH3 in camphanoyl), 1.26 (3H, m,
CH2CH of leucine side chain), 1.46 and 1.49 (each 3H, s, CH3-
20), 1.68, 1.93, 2.23, and 2.51 (each 2H, m, CH2 in camphanoyl
group), 2.49 (3H, s, CH3-4), 3.47 (1H, m, leucine NCHCO),
5.16 (2H, s, CH2-3), 5.45 (1H, d, J¼4.8 Hz, H-30), 6.64 (1H, d,
J¼4.8 Hz, H-40), 6.87 (1H, d, J¼8.8 Hz, H-6), 7.63 (1H, d,
J¼8.8 Hz, H-5). MS m/z (%) 780.7 (Mþ1, 100), 649.5 (M-
130, 21); HPLC purity 100.0%.
4.6. [30,40-Di-O-(S)-camphanoyl-4-methyl-(þ)-cis-
kellactone-3-yl]methyl 2-aminoacetate hydrochloride salt (13)
Compound 9 (72 mg, 0.1 mmol) in 2 mL of HCl-ether was
stirred at room temperature for 30 min. After removal of
solvent in vacuo, 13, the hydrochloride salt of 9, was obtained
with mp 216–218 1C; HPLC purity 100.0%.
4.7. In vitro metabolic assay
4.7.1. Materials
Compounds 3 and 5–13 were synthesized and characterized in
our study. NADPH, MgCl2, KH2PO4, K2HPO4 were pur-
chased from Sigma-Aldrich. Reference compounds [fast-meta-
bolized: terfenadine (TER) and moderate-metabolized:
propranolol (PRO)] were also purchased from Sigma-Aldrich.
HPLC-grade acetonitrile and water were purchased from
VWR. Sprague-Dawley rat liver microsomes (Lot No 38290)
were purchased from BD Biosciences (Woburn, MA).
4.7.2. Sample preparation
Stock solutions of the test compounds in DMSO (2 mM) were
dissolved to 0.1 mM with acetonitrile and stored at 4 1C. For
measurement of metabolic stability, the reference compound
PRO and the test compounds 3 and 5–13 were brought to a
ﬁnal concentration of 1 mM with 0.1 M potassium phosphate
buffer at pH 7.4, which contained 0.1 mg/mL SD rat liver
microsomes and 5 mM MgCl2. The ﬁnal incubation volumes
were 300 mL. Reactions were started by adding 60 mL of
NADPH (ﬁnal concentration of 1 mM) and quenched with
600 mL of ice-cold acetonitrile at 5, 15, 30, 60 min time points.
The mixture was then centrifuged at 12,000 rpm for 5 min at
0 1C. Samples at 0 min time point were prepared by adding
600 mL cold acetonitrile ﬁrst, followed by NADPH and
centrifure. The supernatant was collected and 10 mL of the
supernatant was injected directly to LC-MS. The following
controls were also conducted: 1) positive control: liver micro-
somes, NADPH and two mentioned reference compounds
(fast/moderate metabolized clinical drugs); 2) negative control:
omit NADPH (replaced by phosphate buffer).
4.7.3. HPLC-MS conditions
Analysis was carried out on a Shimadzu LC-20AT HPLC with
auto-sampler and PDA detector, and LCMS-20 mass
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electrospray ionization (ESI) mode. An Alltima C18 (5 mm,
150 mm 2.1 mm) column was used with a ﬂow rate of
0.2 mL/min. The isocratic elution was conducted using acet-
onitrile (B) in water (A) at 60% or 75%. The MS conditions
were optimized to detector voltage: þ1.6 kV, acquisition
mode: SIM of the appropriate molecular weights of the testing
compounds. The CDL temperature was 200 1C, heat block
was 230 1C and neutralizing gas ﬂow was 1.5 L/min. The
electrospray ionization was operated in the positive ion mode.
Full-scan spectra were also monitored over the range of
m/z 180–1000.
4.7.4. Calculations
As the degradation of parent compounds 5–13 ﬁt pseudo-ﬁrst-
order kinetics (R240.95), linear regression was used to calculate
the apparent in vitro half-life (T1/2) and intrinsic clearance
(CLint)
10. The measured compound 3 peak height ratios were
converted to percentage drug remaining using the initial time
(0 min) peak height ratio values as 100%. The slope of the linear
regression from logarithm percentage remaining vs. time relation-
ships (kobs) was determined. In vitro T1/2¼0.693/kobs. The
in vitro CLint (in units of mL/min/mg protein) was done using
the following formula: in vitro CLint¼(0.693/in vitro T1/2) (mL
incubation/mg microsomes).
4.8. Pharmacokinetic assay in rat
Male SD rats (180–200 g) were used and triplicates were
performed for each sample. Rats were dosed with a tested
prodrug or parent compound 3 at 20 mg/kg for i.g. adminis-
tration in 10% PEG400. Blood samples were collected at 0, 15,
30, 60, 120, 240, and 360 min and were immediately centri-
fuged (3000 rpm, 20 min) to separate the plasma fractions.
When compound 3 was administrated by intravenous (i.v.)
with a dose of 2 mg/kg, the blood samples were collected at 0,
5, 10, 15, 30, 60, 120, 240, and 360 min (Fig. 3). All obtained
plasma samples were stored at 20 1C until analysis. Con-
centration-versus-time proﬁles were obtained for each analyte,
and standard non-compartmental analysis was performed on
the data using DAS Version 2.0 to recover the area under the
curve (AUC) and other non-compartmental parameters. Bioa-
vailability was estimated by dividing the dose-normalized
AUC(0t) resulting from oral administration by the AUC(0t)
resulting from intravenous administration (where t is the last
time point with measurable drug concentrations in the study).
Calibration curves for testing compounds in plasma were
linear in the concentration range of 10–2000 ng/mL with
correlation coefﬁcients Z0.990 for all curves.
4.9. Water solubility analysis assay
Each tested compound was added in excess to a 1.5 mL tube
containing 1 mL of HPLC grade water at pH 7.4 (phosphate
buffer of K2HPO4), and the mixture stirred with ultrasonicassistance at room temperature for 1 h. The excess solid was
removed by ﬁltration, and the supernatant was dispensed into
glass HPLC vials. The concentration of the samples was
determined by HPLC on an Agilent SB-C18 column
(150 mm 4.6 mm, 5 mm), with a ﬂow rate of 1.0 mL/min
and detection at 320 nm UV wavelength. The samples (10 mL)
were injected and run with a solution of 30% water and 70%
MeCN. For each compound, a standard curve consisting of
ﬁve concentrations (ﬁve-fold stepwise) in MeCN was estab-
lished initially.Acknowledgments
This investigation was supported by grants from the Ministry of
Science and Technology of the People’s Republic of China
(2009ZX09102–008) and Beijing Municipal Science & Technology
Commission (D0206001040191) awarded to Lan Xie, and by NIH
grant number AI 33066 awarded to K. H. LeeReferences
1. Huang L, Kashiwada Y, Cosentino LM, Fan S, Chen CH,
McPhail AT, et al. Anti-AIDS agents 15. Synthesis and anti-
HIV activity of dihydroseselins and related analogs. J Med Chem
1994;37:3947–55.
2. Xie L, Takeuchi Y, Cosentino LM, Lee KH. Anti-AIDS agents
37. Synthesis andstructure-activity relationships of (30R, 40R)-(þ)-
cis-khellactone derivatives as novel poten anti-HIV agents. J Med
Chem 1999;42:2662–72.
3. Xie L, Takeuchi Y, Cosentino LM, McPhail AT, Lee KH. Anti-
AIDS agents 42. Synthesis and anti-HIV activity of disubstituted
(30R, 40R)-30,40-di-O-(S)-camphanoyl-(þ)-cis-khellactone analo-
gues. J Med Chem 2001;44:664–71.
4. Xie L, Yu D, Wild C, Allaway G, Turpin J, Smith PC, et al. Anti-
AIDS agents 52. Synthesis and anti-HIV activity of hydroxy-
methyl (30R, 40R)-30,40-di-O-(S)-camphanoyl-(þ)-cis-khellactone
derivatives. J Med Chem 2004;47:756–60.
5. Huang L, Yuan X, Yu D, Lee KH, Chen CH. Mechanism of
action and resistant proﬁle of anti-HIV-1 coumarin derivatives.
Virology 2005;332:623–8.
6. Suzuki M, Li Y, Smith PC, Swenberg JA, Martin DE, Morris-
natschke SL, et al. Anti-AIDS agents 65: investigation of the
in vitro oxidative metabolism of 30,40-di-O-(S)-camphanoyl-(þ)-
cis-khellactone derivatives as potent anti-HIV agents. Drug Metab
Dispos 2005;33:1588–92.
7. Yoshikawa M, Mishiyama S, Takaiti O. Metabolism of dopamine
prodrug, docarpamine. Hypertens Res 1995;18:211–3.
8. Sugawara M, Huang W, Fei YJ. Transport of valganciclovir, a
ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2.
J Pharm Sci 2000;89:781–9.
9. Yang YH, Aloysius H, Inoyama D, Chen Y, Hu LQ. Enzyme-
mediated hydrolyticactivation of prodrugs. Acta Pharm Sin B
2011;1:143–59.
10. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC,
Maclntyre F, et al. The prediction of human pharmacokinetic
parameters from preclinical and in vitro metabolism data. J
Pharmacol Exp Ther 1997;283:46–58.
